Trial Profile
A Phase II Trial to Assess the Activity of TroVax Alone vs. TroVax Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA 5T4 (Primary) ; Granulocyte macrophage colony stimulating factor; Granulocyte-macrophage colony-stimulating factors
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 24 Mar 2009 Oxford BioMedica added as trial sponsor as reported by ClinicalTrials.gov.
- 20 Mar 2008 Additonal results were reported at the 6th International Symposium on Targeted Anticancer Therapies.
- 26 Jun 2007 Status changed from in progress to completed.